Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

968 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, Abramson JS, Arnason J, Ghosh N, Mehta A, Andreadis C, Solomon SR, Kostic A, Dehner C, Espinola R, Peng L, Ogasawara K, Chattin A, Eliason L, Palomba ML. Wang M, et al. Among authors: ghosh n. J Clin Oncol. 2024 Apr 1;42(10):1146-1157. doi: 10.1200/JCO.23.02214. Epub 2023 Dec 10. J Clin Oncol. 2024. PMID: 38072625 Clinical Trial.
Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry.
Ghosh N, Sharman JP, Gutierrez M, Khan W, Qureshi ZP, Raz A, Girardi V, Krigsfeld GS, Barrientos JC. Ghosh N, et al. Clin Lymphoma Myeloma Leuk. 2024 Sep;24(9):e301-e313. doi: 10.1016/j.clml.2024.05.009. Epub 2024 May 13. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38845276 Free article.
Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.
Hu B, Vaidya R, Ahmed F, Ehsan H, Moyo TK, Jacobs RW, Pang Y, Park S, Wallander ML, Shroff V, Boseman V, Beam T, Elder J, Yountz M, Jennings RD, Howard DS, Avalos B, Copelan EA, Mesa R, Ghosh N. Hu B, et al. Among authors: ghosh n. Transplant Cell Ther. 2024 Nov;30(11):1082.e1-1082.e10. doi: 10.1016/j.jtct.2024.09.007. Epub 2024 Sep 11. Transplant Cell Ther. 2024. PMID: 39270935
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw LY, Jing J, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Chavez JC. Budde LE, et al. Among authors: ghosh n. Nat Med. 2024 Jan;30(1):229-239. doi: 10.1038/s41591-023-02726-5. Epub 2023 Dec 10. Nat Med. 2024. PMID: 38072960 Free PMC article. Clinical Trial.
Biologically Randomized Comparison of Haploidentical Versus Human Leukocyte Antigen-Matched Related Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.
Grunwald MR, Sha W, He J, Sanikommu S, Gerber JM, Ai J, Knight TG, Fasan O, Boseman V, Kaizen W, Chojecki A, Ragon BK, Symanowski J, Avalos B, Copelan E, Ghosh N. Grunwald MR, et al. Among authors: ghosh n. Transplant Cell Ther. 2024 Dec;30(12):1211.e1-1211.e11. doi: 10.1016/j.jtct.2024.09.021. Epub 2024 Sep 26. Transplant Cell Ther. 2024. PMID: 39332808
968 results